Skip to main content
OpenTrials
Completed

NCT Number: NCT00335023

Well Being of Obstetric Patients on Minimal Blood Transfusions

Postpartum haemorrhage (PPH) is one of the top five causes of maternal mortality in developed and developing countries. The most important treatment of PPH is red blood cell (RBC) transfusion. The decision whether to prescribe RBC transfusion is mostly based on postpartum haemoglobin (Hb) values. RBC transfusion should be aimed to reduce morbidity and especially to improve Health Related Quality of Life (HRQoL). The goal of the WOMB study is to assess the effect of RBC transfusion on HRQoL and to confirm the role of HRQoL in deciding whether RBC transfusion is necessary.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The WOMB study is a multicenter trial in patients with PPH, where a restrictive RBC transfusion policy will be compared with a more liberal RBC transfusion policy. Primary outcome in this study is fatigue measured with the MFI questionnaire. Inclusion criteria are: 1) 12-24 h after VD or CS; 2) 4.8 ≤Hb≤ 7.9 g/dL; 3) blood loss ≥ 1000mL or Hb decrease ≥ 1,9 g/dL; 4) age≥ 18 years; 5) no anaemic symptoms. Patients will be randomised for a RBC transfusion or not. The total follow-up period is 6 weeks. HRQoL will be measured at T=0 (12-24 hours postpartum) 3 days, 1, 3 and 6 weeks postpartum. At T=0 and 6 weeks postpartum Hb value will be measured. For the patients who receive a RBC transfusion, the effect of the RBC transfusion will be measured with the Hb value, Hct, platelet and leukocyte count, and the temperature of the patient before and after the RBC transfusion. The sample size is 500 patients: 250 allocated to a RBC transfusion and 250 patients allocated to a restrictive policy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women older than 18 years
  • 12-24 hours after delivery (vaginal or caesarean section)
  • Patients are in a clinical obstetric setting
  • Blood loss of more than 1000 mL or Hb decrease ≥ 1,9 g/dL
  • Hb value between 4.8 g/dL and 7.9 g/dL
  • Working knowledge of the national language
  • Written consent for participating this study (informed consent)

Exclusion criteria

  • Patients with severe preeclampsia/ HELLP syndrome
  • RBC transfusion during or after delivery but before t=0
  • Patients with malignancy
  • Patients with severe congenital haemolytic disease, like thalassemia or sickle cell disease
  • Patients with compromised immunological status, congenital or acquired by medical treatment or infectious disease (eg. HIV)
  • Severe active infectious disease at the time of proposed inclusion
  • Severe cardiac, pulmonary, neurological, metabolic or psychiatric co- morbidity (ASA II/III) at the time of proposed inclusion
  • Severe physical complaints (tachycardia of more than 100 bpm, dyspnoea, syncope, heart problems) at the time of intended inclusion
  • Peripartum death of the newborn, or the newborn being in critical condition on neonatal intensive care

Treatment and study plan

Red blood cell Transfusion

Other

At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.

Primary outcomes

  1. Physical Fatigue

    Time frame: on day 3 postpartum

    measured with the MFI questionnaire

Secondary outcomes

  1. Health related quality of life

    Time frame: delivery - six weeks postpartum

    Health related quality of life measured with the following questionnaires: Euro-Qol, SF-36 and the MFI

  2. Blood usage and the costs

    Time frame: delivery - six weeks postpartum

  3. Hemoglobin increase after transfusion

    Time frame: before- after transfusion

    Hb value and platelet count will be measured before and after red blood cell transfusion

  4. Heart beat, blood pressure, temperature

    Time frame: before- after transfusion

    heart beat per minute, blood pressure, temperature will be measured before and after red blood cell transfusion

  5. Hospital stay

    Time frame: delivery - six weeks postpartum

    the hospital stay after delivery will be compared between both arms. All admissions in the first 6 weeks postpartum will be registered

  6. Physical complications (infections, thromboembolic events, hemodynamic events, cardiac events, neurologic events, secondary HPP, obstetric interventions, 'rescue' RBC transfusion) with WHO CTC grade 2 or more.

    Time frame: delivery - six weeks postpartum

    all complications and admissions in the first 6 weeks postpartum will be registered

Sponsors and collaborators

Lead sponsor

Sanquin Research & Blood Bank Divisions

Other

Collaborators

  • Erasmus Medical Center

Registry information

Acronym: WOMB

Important dates

Study start
2004
Primary completion
2011
First posted
Jun 8, 2006
Registry last updated
Jul 20, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.